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Abstract
a-Conotoxins are peptides isolated from the venom ducts of cone snails that target nicotinic acetylcholine receptors
(nAChRs). They are valuable pharmacological tools and have potential applications for treating a range of conditions in
humans, including pain. However, like all peptides, conotoxins are susceptible to degradation, and to enhance their
therapeutic potential it is important to elucidate the factors contributing to instability and to develop approaches for
improving stability. AuIB is a unique member of thea-conotoxin family because the nonnative ‘‘ribbon’’ disulfide isomer
exhibits enhanced activity at the nAChR in rat parasympathetic neurons compared with the native ‘‘globular’’ isomer.
Here we show that the ribbon isomer of AuIB is also more resistant to disulfide scrambling, despite having a nonnative
connectivity and flexible structure. This resistance to disulfide scrambling does not correlate with overall stability in
serum because the ribbon isomer is degraded in human serum more rapidly than the globular isomer. Cyclizationvia the
joining of the N- and C-termini with peptide linkers of four to seven amino acids prevented degradation of the ribbon
isomer in serum and stabilized the globular isomers to disulfide scrambling. The linker length used for cyclization
strongly affected the relative proportions of the disulfide isomers produced by oxidative folding. Overall, the results
of this study provide important insights into factors influencing the stability and oxidative folding of a-conotoxin
AuIB and might be valuable in the design of more stable antagonists of nAChRs. Antioxid. Redox Signal. 14, 87–95.
Introduction
a -conotoxins are small disulfide-rich peptide toxinsisolated from the venoms of predatory marine snails of the
Conus genus (1, 13, 25, 32). They are generally 12–19 amino
acids in size and specifically inhibit muscle and neuronal
nicotinic acetylcholine receptor (nAChR) subtypes (14). Their
potency and selectivity make them valuable tools in under-
standing the mechanisms involved in ligand–receptor inter-
actions (11) and also engender them with a range of potential
therapeutic applications, most notably for the treatment of
chronic pain (5, 22). However, like many peptides, conotoxins
are potentially limited in their use as therapeutics by their
susceptibility to proteolytic degradation and=or disulfide
bond shuffling, which produces inactive derivatives (3). Such
limitations can be overcome via appropriate delivery routes
or via chemical modification to stabilize them. For instance, a
synthetic version of o-conotoxin MVIIA (‘‘Prialt’’), which is
marketed for the treatment of chronic pain, is infused in-
trathecally to exert its biological effects directly at the site of
action (20, 27). Similarly, a modified version of w-conotoxin
MrIA, Xen2174, is currently undergoing clinical trials for
pain via intrathecal delivery. Xen2174 contains a modified
N-terminus, which ameliorates the aforementioned stability
problems (7). Thus, it is of significant interest to deter-
mine the factors that influence stability, which will enable
the design of novel conotoxins with enhanced therapeutic
stability.
Recently, backbone cyclization has been used as a method
to improve the stability of conotoxins (8, 23). Artificially cy-
clized derivatives of the naturally occurring a-conotoxins MII
(7, 8), ImI (4), and w-conotoxin MrIA (23) all have improved
stability over their linear parent peptides. However, it is of
interest to determine if factors such as the amino acid sequence,
three-dimensional (3D) structure, or cysteine spacing influence
the effectiveness of cyclization. In the present study we cyclized
a-conotoxin AuIB because it has different cysteine spacing and
it significantly differs in sequence from MII, ImI, and MrIA.
a-Conotoxin AuIB, originally isolated from the cone snail
Conus aulicus, comprises 15 amino acid residues and targets
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mainly the a3b4 subtype of the nAChR (24). a-Conotoxins are
classified based on the number of residues within their two
intercysteine loops, and AuIB was the first example of a 4=6
spacing (i.e., having four residues in the first loop and six in
the second loop) in this family of conotoxins. Other 4=6 con-
otoxins have since been found, including Pu1.2, Lp1.6a, and
Lp1.6b, but the number of examples with this cysteine spacing
is still limited (35). The 3D structures of both the globular
(CysI-CysIII, CysII-CysIV) and ribbon (CysI-CysIV, CysII-CysIII)
isomers of AuIB have been determined using nuclear mag-
netic resonance (NMR) spectroscopy (12) and are shown in
Figure 1. The globular isomer has a well-defined structure
displaying the classic a-conotoxin fold, with the major ele-
ment of secondary structure being an a-helix centered around
CysIII (28). By contrast, the ribbon isomer is poorly defined
and lacks regular secondary structure. Despite this lack of
structure, the ribbon isomer inhibits neuronal nAChRs in rat
parasympathetic ganglia with a potency of *10-fold greater
than the globular isomer (12). This finding is unusual for a-
conotoxins because the globular isomer is typically the native
form in the venom and is usually the most potent bioac-
tive conformation. In another illustration of the complexity
of the pharmacology of a-conotoxins, it has been reported that
the globular form of AuIB is more active than the ribbon
isomer on oocyte-expressed a3b4 receptors (30), but this has
recently been shown to be dependent on the stoichiometry of
receptor subunits (16). Further, it is possible there are other
targets for AuIB that have not yet been identified.
In the present study we analyzed the disulfide bond sta-
bility (i.e., susceptibility to disulfide scrambling) as well as the
overall stability of AuIB and a range of cyclic analogs in
serum. We found that the acyclic ribbon isomer is more stable
in the presence of glutathione than the native globular isomer.
By contrast, the ribbon form is rapidly degraded in human
serum, presumably via proteolysis, whereas the globular
isomer remains intact. Backbone cyclization prevented deg-
radation of the ribbon isomer in human serum, providing
strong support for the concept that cyclization is a valuable
general technique for stabilizing conotoxin peptides.
Materials and Methods
Peptide synthesis
All AuIB analogs were synthesized, oxidized, and cyclized
according to previously established protocols used by Dutton
et al. (2002) and Clark et al. (2005) (8, 12). Oxidation and thia-
zip cyclization were performed in a single step in 20% iso-
propanol=80% 100 mM ammonium bicarbonate (pH 7.5) at
room temperature for 24 h at a peptide concentration of
0.8 mg=ml. The conditions for oxidative folding were based
on previous folding studies on the linear peptides (12). Pep-
tides were purified by high-performance liquid chromatog-
raphy (HPLC) using a Vydac C18 column at a 1% gradient
(increasing 1% solvent B per minute). Solvent A is 0.1% tri-
fluoroacetic acid (TFA) in water and solvent B is 0.05% TFA in
90% acetonitrile. The purity of the products was verified by
using analytical C18 HPLC and by electrospray mass spec-
trometry. The globular isomer of cAuIB-4 and the ribbon
isomer of acyclic AuIB were synthesized using selective pro-
tection of the cysteine residues with S-acetamidomethyl
groups as described previously (19).
NMR spectroscopy
Samples for NMR contained *2–3 mM peptide in 2H2O or
95% H2O=5%
2H2O at pH 3–5.5. Total correlation spectros-
copy (TOCSY), nuclear overhauser enhancement spectros-
copy (NOESY), double quantum filtered correlation
spectroscopy (DQF-COSY), and exclusive correlation spec-
troscopy (ECOSY) spectra were acquired on Bruker Avance
600 MHz or 750 MHz spectrometers as described previously
(10). Briefly, the homonuclear spectra recorded included
DQF-COSY, TOCSY, using a MLEV17 spin lock sequence
with an isotropic mixing time of 80 ms, ECOSY, and NOESY,
with mixing times of 150, 250, and 350 ms. In DQF-COSY and
ECOSY experiments, the water resonance was suppressed by
low-power irradiation during the relaxation delay. For the
TOCSY and NOESY experiments, water suppression was
achieved using a modified water suppression by gradient-
tailored excitation (WATERGATE) sequence. Two-dimensional
spectra were generally collected over 4096 data points in the f2
dimension and 512 increments in the f1 dimension over a
spectral width of 12 ppm. Spectra were analyzed and assigned
using the program XEASY (15), using the well-established
sequential assignment protocol (34).
Structure calculations
Cross-peaks in NOESY spectra recorded in 95% H2O=5%
2H2O with mixing times of 250 ms were integrated and cali-
brated in XEASY, and distance restraints were derived using
CYANA (17). Backbone dihedral angle restraints were de-
rived from 3JHNHa coupling constants measured from line
shape analysis of antiphase cross-peak splitting in the DQF-
COSY spectrum. Angles were restrained to 1208 308 for
3JHNHa >8.5 Hz and to 608 308 for 3JHNHa <5 Hz. Stereo-
specific assignments of b-methylene protons and w1 dihedral
angles were derived from 3Jab coupling constants, measured
from ECOSY spectra, in combination with NOE peak inten-
sities. Preliminary structures were calculated using a torsion
FIG. 1. Three-dimensional structures of AuIB. An overlay
of the 20 lowest energy structures is given on the left and the
secondary structure is highlighted on the right. The globular
isomer (PDB code 1mxn) is shown on the top and the ribbon
(PDB code 1mxp) on the bottom.
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angle simulated annealing protocol within CYANA, and final
structures were calculated using simulated annealing and
energy minimization protocols within CNS as described
previously (29). Structures were analyzed using PROMOTIF
and PROCHECK (18, 21).
Stability assays
The thiol stability of the peptides was assessed using re-
duced glutathione as described previously (3). Briefly, peptide
samples (0.25 mM) were dissolved in a solution containing
0.25 mM reduced glutathione in 100 mM phosphate buffer
and 1 mM EDTA (pH 7.2) and incubated at 378C. Aliquots
were taken at various time intervals, quenched with 4% TFA,
and analyzed by reverse-phase HPLC (RP-HPLC) to deter-
mine if disulfide scrambling had occurred.
Serum stability assays were carried out in 100% human
male serum (Sigma) using a 20 mM final peptide concentra-
tion. Serum was centrifuged at 14,000 g for 10 min to remove
the lipid component, and the supernatant was incubated at
378C for 15 min before the assay. Each peptide was incubated
in serum at 378C and 40ml triplicate aliquots were taken out at
time points 0, 3, 6, 8, and 21 h. Each serum aliquot was
quenched with 40 ml of 6 M urea and incubated for 10 min at
58C. Then, 40ml of 20% trichloroacetic acid was added to each
serum aliquot and incubated for another 10 min at 58C to
precipitate serum proteins. The samples were centrifuged at
14,000 g for 10 min, and 100 ml of the supernatant was ana-
lyzed on RP-HPLC using a linear gradient of solvent B
(0.3 ml=min flow rate). The percentage recovery of peptides
was detected by integration at 215 nm.
Biological assays
Plasmids with cDNA encoding the rat a3 and b4 nAChR
subunits were obtained from J. Patrick (Baylor College of
Medicine). All oocytes were injected with a total of 5 ng of
cRNA and then kept at 188C for 2–5 days before recording in
ND96 buffer (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM
MgCl2, and 5 mM HEPES at pH 7.4) supplemented with
50 mg=L gentamycin, 5 mM pyruvic acid, and 5% horse se-
rum. Electrodes were pulled from borosilicate glass (Harvard
Apparatus Ltd.) and had resistances of 0.3–1.5 MO after filling
with 3 M KCl. All experiments were performed at room
temperature (218C–238C). Oocytes expressing a3b4 nAChRs
were voltage clamped at 80 mV and membrane current was
recorded using a two-electrode voltage virtual ground circuit
on a GeneClamp 500B amplifier (Molecular Devices) or an
automated workstation with eight channels in parallel, in-
cluding drug delivery and on-line analysis (OpusXpress
6000A workstation; Molecular Devices). Data were digitized
at 500 Hz and low-pass filtered at 200 Hz. During recordings,
oocytes were perfused continuously at a rate of 2–3 ml=min,
with 300 s incubation for the conopeptide. Acetylcholine
(ACh; 50–100 mM) was applied for 2 s at 5 ml=min, with 3–10-
min washout periods between applications, and peptides
were bath applied and coapplied with the agonist. Peak cur-
rent amplitude was measured before and following incuba-
tion of the peptides. All electrophysiological data were pooled
(n¼ 3–7 for each data point) and represent arithmetic
means standard error of the mean. Concentration–response
curves for antagonists were fitted by unweighted nonlinear
regression to the logistic equation: Ex¼Emax Xn=(Xnþ IC50n),
where Ex is the response, X is the antagonist concentration,
Emax is the maximal response, n is the slope factor, and IC50 is
the antagonist concentration that gives half-maximal inhibi-
tion of the agonist response. Curves were fitted with Sigma-
Plot 8.0 ( Jandel Corporation). A one-way analysis of variance
was used to compare modified and nonmodified conotoxins.
Results
A series of AuIB analogs were synthesized using t-butox-
ycarbonyl (Boc) chemistry and cleaved from the resin with
hydrogen fluoride. A list of the sequences is given in Figure 2;
both the ribbon and globular disulfide isomers were made for
each AuIB analog. The cyclic analogs of AuIB are denoted
cAuIB, followed by a number corresponding to the number of
residues in the linker used to join the N- and C-termini. The
peptides were oxidatively folded in 20% isopropanol=80%
ammonium bicarbonate buffer (*pH 8). For the cyclic pep-
tides, both cyclization and oxidation were achieved in one
step using conditions outlined previously (8). The disulfide
isomers were purified by RP-HPLC and analyzed by mass
spectrometry and NMR to confirm their disulfide connectiv-
ity. For all sequences the ribbon isomer eluted earlier on RP-
HPLC than the globular isomer, but the relative proportions
of globular and ribbon isomers varied significantly for
the different peptides synthesized, as shown in Figure 3. The
ribbon isomers gave broader peaks on RP-HPLC than the
globular isomers, suggesting the presence of multiple con-
formations in exchange with each other for the ribbon iso-
mers. The beads isomer (CysI-CysII, CysIII-CysIV) was not
detected in any of the chromatograms.
NMR assignments of the purified peptides were made
using established techniques (34) and a complete sequential
assignment was obtained for all peptides. The assignments
were compared with those reported previously for the cor-
responding acyclic peptides (12). From this analysis it was
clear that the cyclic globular and ribbon forms had very
similar aH NMR chemical shifts to their respective acyclic
forms, as shown in Figure 4. All globular isomers of cAuIB
(and linear, native AuIB) had trans conformations for all Pro
residues in the structures, whereas all ribbon isomers of cAuIB
differed by having a cis conformation for the peptide bond
preceding Pro7.
In general, the ribbon isomers had a smaller dispersion of
chemical shifts of peaks in the amide region of the NMR
spectra than the globular isomers, suggesting less well-
defined structures for the ribbon isomers. Spectra were re-
corded at pH 3.5 and 5.5 to determine if pH-dependent
FIG. 2. Sequences of cyclic analogs of AuIB. The linker
sequences used to cyclize AuIB are shown on the left and
represented schematically in terms of the three-dimensional
structure on the right.
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structural changes were present, but no significant differences
in chemical shifts were observed (data not shown), suggesting
that the global folds were unaffected by pH. Therefore, the 3D
structures for the globular isomers of cAuIB-4, cAuIB-5, and
cAuIB-6 were determined at pH 3.5, where the exchange of
the amide protons is slower than at higher pH and high-
quality spectra could be obtained. Structures were not calcu-
lated for the ribbon isomers because their spectra generally
contained fewer NOEs than the globular isomers, consistent
with a high degree of conformational flexibility. In support of
this flexibility, a trial structure calculation for the ribbon form
of cAuIB-5 gave a disordered ensemble of structures, similar
to that reported previously for acyclic ribbon AuIB (12).
Families of 50 structures were calculated for the globular
isomers using a torsion angle dynamics protocol within CNS
(6), using procedures described previously (9). A summary of
the geometric and energetic statistics for the globular isomers
of cAuIB-4, cAuIB-5, and cAuIB-6 is given in Table 1. The 20
lowest energy structures were chosen as the final ensembles
and the structures had no NOE violations of >0.3 A˚ and no
dihedral violations of >38. In all globular structures, residues
six to nine form an a-helix characteristic of a-conotoxins (28).
The structures had pairwise root mean square differences
(RMSDs) of 0.48, 0.28, and 2.30 A˚ over the backbone atoms for
globular cAuIB-4, cAuIB-5, and cAuIB-6, respectively. These
backbone RMSDs decreased to 0.23 and 1.10 A˚, for the glob-
ular isomers of cAuIB-4 and cAuIB-6, respectively, when the
overlay was done over residues 1–15 (i.e., the native se-
quence). The decreased RMSD when only the native residues
of the cyclic peptides are overlaid indicates that the disorder
in these cyclic peptides is primarily located in the linker re-
gion. In contrast, when the 20 lowest structures of globular
cAuIB-5 are overlayed over only the native residues, the
RMSD is only reduced to 0.24 A˚ over the backbone, which
suggests that the linker region is relatively ordered in this
peptide. The well-defined structure of the linker region con-
trasts to the somewhat disordered linkers seen in other cyclic
conotoxins (8, 23), suggesting that this particular linker is
structurally well tolerated in AuIB.
Figure 5 shows backbone superimpositions of ensembles of
the 20 lowest energy structures of globular cAuIB-4, cAuIB-5,
and cAuIB-6, oriented to display the native a-helix region
(Pro6-Phe9). The structures have good covalent geometry,
indicated by only small deviations from ideal bond lengths
and bond angles.
Peptide stability
Incubation of the globular isomers of cyclic and linear AuIB
analogs in a glutathione buffer generally resulted in disulfide
bond shuffling preferentially to the ribbon isomer. The pres-
ence of the beads isomer, which contains a vicinal disulfide
bond, was not observed in these experiments, and in subse-
quent analyses only the presence or absence of the globular
and ribbon isomers was analyzed. Similar to the analytical
RP-HPLC traces of the purified peptides following oxida-
tion=cyclization, the globular isomers resulted in sharp peaks,
whereas the ribbon isomers resulted in broad peaks. To de-
termine the degree of disulfide bond shuffling, the area under
each peak (recorded at l¼ 214 nm) was calculated and the
proportion of parent isomer remaining was determined, as
shown in Figure 6. In these experiments there was a signifi-
cant difference between the disulfide shuffling of the rib-
bon isomers and the globular isomers: the globular isomers
FIG. 3. Oxidative folding of AuIB and cyclic analogs.
Reverse-phase high-performance liquid chromatograph
showing the ribbon isomers eluting earlier than the globular
isomers (globular and ribbon are referred to as g and r, re-
spectively). The percentages of the isomers vary significantly
throughout the analogs.
FIG. 4. Secondary aH chemical shifts of AuIB and cyclic
analogs. The secondary aH shifts were calculated by sub-
tracting the random coil shifts (33) from the experimental aH
shifts. The globular isomers are shown on top and the ribbon
isomers on the bottom.
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shuffled and reached equilibrium with a majority of ribbon
isomer present, whereas the ribbon isomers underwent very
little disulfide shuffling. Of all the analogs, ribbon cAuIB-4
underwent the least amount of glutathione-assisted disulfide
bond shuffling, retaining nearly 100% of the starting isomer
after 10 h. Conversely, globular cAuIB-6 underwent the most
glutathione-assisted shuffling, with only *20% of the parent
isomer remaining after 10 h. Interestingly, acyclic globular
AuIB underwent significantly more disulfide bond shuffling
than the cyclic peptides having five- or seven-residue linkers.
Serum stability
The stability in human serum of AuIB and its analogs was
investigated to determine the effects of disulfide connectivity
and backbone cyclization. RP-HPLC was used to determine
the extent of degradation of the peptides, and all of the cyclic
peptides were stable in human serum over a 24-h period, as
shown in Figure 6. The linear form with the native, globular
connectivity was also stable, but the ribbon isomer was sig-
nificantly degraded. After 8 h, only*40% of the linear ribbon
AuIB remained, decreasing to <5% after 24 h. Thus, the
globular connectivity is stable in human serum, and cycliza-
tion stabilizes the ribbon conformer to degradation.
Electrophysiological recordings in Xenopus oocytes
The activities of cyclized analogs of AuIB a-conotoxins on
ACh-evoked currents were examined and compared with
AuIB. Globular AuIB reversibly inhibited ACh-evoked cur-
rents mediated by a3b4 nAChRs with an IC50 of 2.5 0.6 mM
(n¼ 7) and a Hill coefficient of 1.5 (Fig. 7A). Globular cAuIB
analogs with linkers ranging from four to seven amino acids
all exhibited varying degrees of inhibition, with cAuIB-5
having an apparent IC50 of 9.1 2.6 mM (n¼ 7) and a Hill
coefficient of 0.9. At the maximum concentration (10 mM)
tested, AuIB inhibited the ACh-evoked current by >95%,
whereas cAuIB-5 inhibited the peak current amplitude by
only *50%. We were unable to determine IC50 values for
other cAuIB analogs owing to limited material. A direct
comparison of the inhibition of a3b4 nAChRs by globular
cAuIB analogs was carried out at a fixed concentration of
3mM. AuIB reduced the ACh-evoked current amplitude to
50% 13% (n¼ 4) of the control peak amplitude ( p< 0.05),
compared with cAuIB-4, cAuIB-5, cAuIB-6, and cAuIB-7,
which reduced the currents to 65% 6% (n¼ 4, p< 0.05),
81% 3% (n¼ 3, p¼ 0.07), 93% 6% (n¼ 4, p¼ 0.3), and
90% 7% (n¼ 4, p¼ 0.5) of control current amplitude, re-
spectively (Fig. 7B).
Cyclic ribbon AuIB analogs were compared with acyclic
ribbon AuIB at a fixed concentration of 10 mM. Preincubation
with the acyclic ribbon AuIB reduced a3b4 nAChR-mediated
current amplitude to 55% 2% (n¼ 6) of control ( p< 0.05)
(Fig. 8A). Preincubation with cAuIB-4 reduced ACh-induced
currents to 78% 3% of control (n¼ 3, p< 0.05), whereas
cAuIB-5, cAuIB-6, and cAuIB-7 did not change the current
amplitude significantly, that is, 113% 6% (n¼ 3, p¼ 0.2),
Table 1. Structure Statistics for Globular Isomers of Cyclic AuIB Analogs
cAuIB-4 cAuIB-5 cAuIB-6
Experimental restraints
Sequential NOEs 75 67 43
Medium range NOEs 43 22 30
Long range 21 11
Dihedral angles 19 15 14
Mean RMSDs from experimental restraintsa
NOE distances (A˚) 0.009 0.001 0.04 0.22 0.04 0.003
Dihedral angles (8) 0.24 0.14 0.45 0.17 0.34 0.24
Mean RMSDs from idealized covalent geometry
Bonds (A˚) 0.003 0.0003 0.003 0.0003 0.004 0.0002
Angles (8) 2.06 0.04 0.49 0.04 0.52 0.06
Impropers (8) 0.14 0.02 0.37 0.05 0.35 0.07
Mean energies (kcal=mol)
ENOE 6.26 2.8 10.28 1.2 8.33 1.2
EDIH 0.14 0.14 0.21 0.16 0.13 0.18
EBOND 2.32 0.40 2.80 0.53 3.18 0.43
EANGLE 13.96 1.8 16.13 2.55 18.55 4.3
EIMPROPER 2.15 0.33 2.84 0.86 2.60 1.1
EVDW 30.64 3.8 40.54 3.6 24.42 7.5
Atomic RMSDs (A˚)b
Backbone atoms (residues 1–15) 0.23 0.11 0.28 0.18 1.10 0.47
Heavy atoms (residues 1–15) 0.61 0.17 0.84 0.27 1.58 0.45
Ramachandran statistics (%)c
Residues in most favored regions 93.8 92.7 61.5
Residues in additionally allowed regions 6.2 7.3 38.5
Residues in generously allowed regions 0 0 0
Residues in disallowed regions 0 0 0
aThe values are the mean standard deviation.
bAtomic RMSDs are the pairwise root mean square differences for the family of structures.
cProcheck NMR was used to calculate the Ramachandran statistics for residues 1–15.
NMR, nuclear magnetic resonance; NOE, nuclear overhauser enhancement.
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93% 2% (n¼ 3, p¼ 0.1), and 98% 2% (n¼ 4, p¼ 0.3) of
control values, respectively (Fig. 8B). Inhibition of ACh-
evoked currents by cAuIB-4 was significantly less compared
with the acyclic ribbon AuIB (n¼ 3, p< 0.01).
Discussion
In the present study we synthesized cyclic forms of a-
conotoxin AuIB using native chemical ligation, with linker
sizes ranging from four to seven residues. Cyclization has
been shown to be useful in stabilizing conotoxins and en-
hancing their therapeutic potential (8, 23). However, the
effectiveness of this technique on a range of conotoxins and,
in particular, the influences of cyclization on structure
and stability have not been fully explored. In the present
study we analyzed the oxidative folding, 3D structures,
and disulfide and serum stability of cyclic forms of AuIB
compared with acyclic forms, all of which have provided
insights into factors influencing the stability of AuIB. Dis-
ulfide bond stability in vivo is a potential limitation in the
use of disulfide-rich peptides as drugs, given that gluta-
thione is present in blood in high concentrations and can
facilitate disulfide bond exchange (3, 26, 31). Therefore,
understanding the factors influencing the disulfide stability
of a-conotoxins should be useful in studies aimed at ex-
ploiting their therapeutic potential.
Significant differences were observed in the oxidative fold-
ing reactions of AuIB and its cyclic analogs. Under the folding
conditions used in this study, which did not involve directed
disulfide formation, the major product of oxidative folding of
the reduced acyclic peptide was the globular isomer (Fig. 2).
However, on oxidation of the reduced cyclic analogs, the
proportions of the resulting globular or ribbon isomers varied
considerably with linker size. The smallest linker used (four
residues in cAuIB-4) resulted predominately in ribbon isomer.
For this analog the yield of the globular isomer was so low
that selective protection of the disulfide bonds in a separate
synthesis was required for its isolation. By contrast, both
globular and ribbons isomers were isolated from the nondi-
rected oxidation of cAuIB-5, cAuIB-6, and cAuIB-7, with an
increasing amount of ribbon isomer obtained as the linker
length was increased (Fig. 2).
Given that the length of the linker appeared to be influ-
encing the oxidative folding outcomes for the cyclic AuIB
analogs, it was of interest to determine their structures to es-
tablish the reason for this influence. Three-dimensional
FIG. 5. Three-dimensional structures of cAuIB-4,
cAuIB-5, and cAuIB-6. A superposition of the 20 lowest
energy structures is shown on the left with the corre-
sponding secondary structure representations on the right.
Structures were determined using nuclear magnetic reso-
nance spectroscopy; the four cysteine residues are num-
bered with Roman numerals, the disulfide bonds are
shown in ball and stick format, and the helixes are shown
as thickened ribbons.
FIG. 6. Disulfide and serum stability of AuIB and cyclic
analogs. (A) AuIB and the cyclic analogs were incubated in
glutathione solution (see Materials and Methods section)
and the proportion (expressed as a percentage) of the
original isomer is plotted relative to time. (B) Stability of
AuIB analogs in human serum. The stability of the peptides
in human serum was determined over a 24-h period. All
analogs were stable with the exception of the acyclic ribbon
isomer.
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structures of the cyclic ribbon isomers were not determined
because of a relative lack of NOEs to define their structures.
The small number of NOEs is likely to be a consequence of
flexibility in the ribbon isomers. However, the 3D structures
of the globular isomers of cAuIB-4, cAuIB-5, and cAuIB-6
were determined and it was found that a well-defined char-
acteristic a-conotoxin fold is maintained in all three analogs.
The linker for cAuIB-6 is more disordered than for the analogs
with shorter linkers, presumably as a result of flexibility in this
region of the structure. Although the structure of cAuIB-7 was
not determined, the residues in the linker region have aH
chemical shifts very close to random coil (Fig. 4), consistent
with the linker being disordered in this peptide as well. The
higher disorder in the structures as the linker size increases
correlates with a higher production of ribbon isomer with
increasing linker size, suggesting that the disordered linkers
might preferentially destabilize the globular form. However,
this explanation is inconsistent with the high proportion of
ribbon isomer formed in the oxidative folding of cAuIB-4,
where the linker is well defined. Overall, the five-residue
linker was optimal for forming the globular isomer under the
in vitro folding conditions used in the present study.
An electrophysiological study of a3b4 nAChRs expressed
in oocytes indicated that cyclization of either globular or
ribbon AuIB reduces their potency relative to the acyclic
forms. The potency of the cyclized AuIB analogs decreases
with increasing linker length such that ribbon cAuIB-7 ex-
hibits no effect on ACh-induced currents, and globular cAuIB-
7 shows only minimal activity.
The ribbon cAuIB analog, cAuIB-4, inhibited (*20%) a3b4
nAChRs at a concentration of 10mM, whereas the other ribbon
analogs were all inactive. In contrast, the inhibition was more
pronounced with cyclic globular cAuIB analogs tested at
3mM. The native AuIB inhibited the ACh-evoked current by
*50% and the cyclic analogs exhibited an increase in nAChR
inhibition as the linker length was shortened: from 10% in-
hibition observed for globular cAuIB-7 to 35% inhibition for
globular cAuIB-4 at 3 mM (Fig. 7B).
The cAuIB-4 analog of both globular and ribbon isoforms
was the most potent of all the cyclic analogs tested on a3b4
nAChRs. This indicates that shorter linker lengths may
be optimal for cyclization of AuIB a-conotoxin. However, the
reduced activity of cyclized AuIB analogs should not be
generalized to all conotoxins, given that some cyclic analogs
FIG. 7. Electrophysiological assays of globular AuIB
analogs at a3b4 nAChRs expressed in Xenopus oocytes. (A)
Representative ACh-evoked currents obtained in the absence
(control) and presence of 3mM AuIB (globular) and cAuIB-4
(globular). (B) Concentration–response relationships ob-
tained for the inhibitory effects of AuIB (globular) analogs.
FIG. 8. Electrophysiological assays of ribbon AuIB ana-
logs at a3b4 nAChRs expressed in Xenopus oocytes. (A)
Representative ACh-evoked currents obtained in the absence
(control) and presence of AuIB (ribbon) and cAuIB-4 (ribbon)
(10mM). (B) Bar graph of normalized peak current ampli-
tudes showing comparison of inhibitory effects of AuIB
[ribbon] analogs tested at 10mM concentration.
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of MII conotoxin have been previously shown to retain near
full biological activity compared with nonmodified MII (8).
Analysis of the disulfide scrambling, as shown in Figure 4,
revealed that all of the ribbon isomers scrambled to a lesser
extent than the globular isomers. This higher stability of the
ribbon isomers is surprising given the apparently disordered
structures of the ribbon isomers and their nonnative disulfide
connectivity. cAuIB-5 and cAuIB-7 had higher relative pro-
portions of globular isomer remaining after incubation with
glutathione than the acyclic globular isomer, indicating that
cyclization can improve the stability of the globular isomer to
shuffling. Interestingly, the relative proportion of globular
isomer remaining after incubation with glutathione (Fig. 6)
does not correlate with the relative proportions obtained in
the oxidative folding reactions (Fig. 3). Further, analysis of the
surface exposure of the disulfide bonds in the structures of
cAuIB-4, 5, and 6 indicates that surface exposure of the
disulfide bonds does not correlate with stability in the shuf-
fling assay. Therefore, it appears that the overall fold con-
tributes to the stability of the disulfide bonds rather than
simply the surface exposure of the cysteine residues, which
might be considered as a measure of access to reducing=
oxidizing agents in solution.
The disulfide scrambling in glutathione has been previ-
ously examined for a-conotoxins ImI (3) and PnIA (19). In-
cubation of the globular isomer of ImI in a glutathione buffer
resulted in shuffling to*50% each of the globular and ribbon
isomers. Analysis of the globular isomers of an analog of PnIA
and truncated forms revealed that the full-length peptide with
a 4=7 intercysteine spacing, and a 4=6 version, resulted in
*40% of the globular isomer left after incubation. Therefore,
these variants of PnIA behave in a similar manner to that
observed for the acyclic form of AuIB, which might be related
to the similar loop spacings of these peptides. The globular
isomers of the truncated forms of PnIA with 4=5, 4=4, and 4=3
loop spacings were very unstable in the glutathione shuffling
assay and predominately converted to the ribbon isomer. This
high level of shuffling contrasts with observations for ImI,
which has a 4=3 loop spacing (3). Overall, the results indicate
that the disulfide stability of the a-conotoxins is highly de-
pendent on the sequence and loop spacing.
In contrast to the disulfide scrambling experiments, all of
the AuIB peptides tested in the present study, with the ex-
ception of the linear ribbon isomer of AuIB, were stable in
human serum. Although the ribbon isomers of the cyclic
forms of AuIB appear to have disordered structures, similar to
the linear form, cyclization of the backbone clearly has a sig-
nificant influence on the stability of AuIB and highlights the
importance of this approach in stabilizing disulfide-rich
peptides. This approach has been successfully applied to a-
conotoxin MII and w-conotoxin MrIA to stabilize them (8, 23).
Given that the ribbon form of AuIB is bioactive (12), stabili-
zation by cyclization might be useful for the therapeutic use of
this peptide.
Selenocysteine substitutions (3) have also been used to
stabilize the disulfide bonds of conotoxins. Analogs of ImI
with selenocysteine did not shuffle in glutathione in contrast
to the native peptide (3). However, there might be limitations
in the use of selenocysteine-containing compounds as thera-
peutics because of potential toxicity (2), and cyclization seems
to be a preferred alternative method for stabilizing the dis-
ulfide connectivities of conotoxins.
In summary, we have shown that cyclization of AuIB in-
fluences its in vitro oxidative folding outcomes and that the
ribbon isomers are more resistant to disulfide scrambling than
the globular isomers. This is unusual considering that glob-
ular isomers are typically the native forms found in venom
and are generally more potent against nAChRs. Cyclization
improves the disulfide stability of the globular isomers and
dramatically improves the serum stability of the ribbon iso-
mers. The ribbon isomer for AuIB is bioactive, and therefore,
stabilization of this analog might have potential therapeutic
applications, where in vivo stability is important. Overall,
these results provide insight into the disulfide stability of a-
conotoxin AuIB and this information should be valuable in
the design of more stable antagonists of nAChRs.
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ACh¼ acetylcholine
Boc¼ t-butoxycarbonyl
DQF-COSY¼double quantum filtered correlation
spectroscopy
ECOSY¼ exclusive correlation spectroscopy
nAChR¼nicotinic acetylcholine receptor
NMR¼nuclear magnetic resonance
NOESY¼nuclear overhauser enhancement
spectroscopy
RMSD¼ root mean square difference
RP-HPLC¼ reverse-phase high-performance liquid
chromatography
TFA¼ trifluoroacetic acid
TOCSY¼ total correlation spectroscopy
WATERGATE¼water suppression by gradient-tailored
excitation
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